Understand reactor design equations for batch, CSTR, and plug flow reactors. A practical guide for catalytic scientists using AMI lab reactor instruments.
Differential scanning calorimetry is one of the most versatile analytical techniques available to pharmaceutical scientists. Its most widely recognised outputs — melting point and glass transition temperature — are the starting point for understanding how a drug compound behaves under processing and storage conditions. But a less commonly discussed differential scanning calorimetry application goes further: using the calorimetric data that DSC measures — specifically heat of fusion (ΔHf) and melting temperature (Tm) — to calculate the theoretical solubility ratio between two polymorphic forms of the same drug compound.
This article demonstrates how DSC-measured calorimetric data for two crystal forms of carbamazepine feeds into a thermodynamic solubility equation to predict the relative solubility of each polymorph across a range of temperatures. The results reveal a fundamental principle in pharmaceutical preformulation: polymorphic solubility differences are typically modest — but for poorly soluble drugs, even modest differences carry significant bioavailability consequences.
All calorimetric analysis described is performed using the AMI DSC 600 differential scanning calorimeter — part of AMI’s range of thermal analysis instruments for pharmaceutical, polymer, and advanced materials characterization.
Polymorphism is the ability of a solid compound to exist in more than one crystalline form, with each form having a distinct arrangement of molecules in the crystal lattice. Polymorphic forms of the same compound share identical molecular formula and chemical connectivity but differ in their three-dimensional packing — producing measurably different physical properties:
|
Property |
Why It Differs Between Polymorphs |
Pharmaceutical Consequence |
|---|---|---|
|
Melting point |
Different crystal packing = different lattice energy |
Identifies which form is thermodynamically stable; determines processing temperature limits |
|
Heat of fusion (ΔHf) |
Higher ΔHf = more energy needed to disrupt the crystal lattice |
Directly determines theoretical solubility via thermodynamic equation; higher ΔHf = lower solubility |
|
Solubility |
Metastable forms have higher free energy → dissolve more readily |
Governs oral bioavailability for BCS Class II/IV drugs; higher-solubility form may dissolve faster in GI tract |
|
Density |
Different packing efficiency |
Affects compressibility and tablet hardness in solid dosage form manufacturing |
|
Crystal habit |
Different preferred growth faces |
Impacts filterability, flow, and content uniformity in formulation |
Polymorphism is ubiquitous in drug development — the majority of organic pharmaceutical compounds are capable of forming multiple crystal forms. Regulatory agencies including the FDA and EMA require polymorph characterization and control for approved solid dosage forms, particularly for compounds with poor aqueous solubility (BCS Class II and IV) where the polymorphic form directly impacts drug absorption.
|
Related reading: For an introduction to differential scanning calorimetry principles and instrument configuration, see our article on differential scanning calorimetry. For a worked example of DSC applied to polymorph identification and TGA combined with DSC for pharmaceutical compound characterization, see thermal analysis in the pharmaceutical field. |
|---|
The relationship between a crystal form’s solubility and its calorimetric properties is given by a well-established thermodynamic equation that relates the mole fraction solubility X to the heat of fusion ΔHf, the melting temperature Tm, the solution temperature T, and the heat capacity change ΔCp on melting:
|
log(X) = −(ΔHf / 2.303R) × (1/T − 1/Tm) + (ΔCp / 2.303R) × [(1 − Tm/T) − ln(Tm/T)] — Equation (1), thermodynamic solubility-fusion relationship where X = mole fraction solubility, R = gas constant, T = solution temperature (K), Tm = melting point (K) |
|---|
This equation has a critical implication for polymorph analysis: if the same equation is applied to two polymorphs of the same compound, each with its own experimentally measured ΔHf and Tm, the equations can be solved simultaneously to derive:
This is the key differential scanning calorimetry application demonstrated in this article: using DSC to measure ΔHf and Tm for two crystal forms, then using those values in Equation (1) to predict the solubility ratio profile — a property directly relevant to bioavailability prediction, formulation selection, and regulatory polymorph control strategy.
Carbamazepine (Figure 1; alt text: chemical structure of carbamazepine dibenzazepine ring system with amide group) is an anticonvulsant drug widely prescribed for epilepsy and trigeminal neuralgia. It exists in at least four anhydrous polymorphic forms and one dihydrate. Forms I and III are both anhydrous and represent a metastable-stable polymorph pair that has been extensively studied — making carbamazepine a benchmark compound for pharmaceutical polymorph characterization methodology.
The two forms display significantly different calorimetric properties when measured by DSC:
|
Property |
Carbamazepine Form I |
Carbamazepine Form III |
|---|---|---|
|
Thermodynamic status |
Metastable |
Thermodynamically stable |
|
Melting point (Tm) |
189°C |
174°C |
|
Heat of fusion (ΔHf) |
26 kJ/mol |
29 kJ/mol |
|
Melting point difference |
— |
15°C lower than Form I |
|
ΔHf difference |
— |
3 kJ/mol higher than Form I |
These values are directly measurable by DSC from the melting endotherm of each pure polymorph: the peak temperature of the melting endotherm gives Tm, and integrating the area under the endotherm peak gives ΔHf. The DSC 600‘s high-precision heat flow sensor and precise integration tools make this determination reliable and reproducible at the sub-degree and sub-kJ/mol level required for accurate solubility modeling.
Using the measured ΔHf values for Forms I and III (ΔHf difference = 3.0 kJ/mol), Equation (1) was applied to both forms simultaneously. The resulting solubility ratio — Form I (metastable) relative to Form III (stable) — was calculated as a function of temperature from near-ambient to 150°C. To assess the sensitivity of the result to ΔHf uncertainty, theoretical curves were also generated for larger ΔHf differences (4.5, 6.0, 7.5, and 9.0 kJ/mol) while holding melting points constant.
Figure 2 (alt text: solubility ratio graph for carbamazepine Forms I and III vs temperature for ΔHf differences from 3.0 to 9.0 kJ/mol) shows a key finding: even at the highest theoretical ΔHf difference (9.0 kJ/mol — three times the measured value), Form I would be at most approximately three times more soluble than Form III at room temperature. At the actual measured ΔHf difference of 3.0 kJ/mol, the solubility ratio at room temperature is considerably smaller.
|
Key finding from ΔHf analysis: Heat of fusion differences between polymorphs have a modest effect on solubility ratio. Even tripling the actual measured ΔHf difference produces a solubility ratio well below 3:1 at room temperature. This places an upper bound on how much solubility advantage a metastable polymorph can realistically offer. |
|---|
In the second simulation, the actual ΔHf values of both polymorphs were held constant at their measured values, while the melting point difference between the two forms was systematically varied over a wide range — from 0°C (identical melting points) up to 37.5°C — which is more than double the actual 15°C difference between Forms I and III.
Figure 3 (alt text: solubility ratio graph for carbamazepine Forms I and III vs temperature for melting point differences from 0.0 to 37.5°C) shows an even more striking result: even with a melting point difference of 37.5°C — an exceptionally large difference rarely encountered in practice — Form I would still be less than twice as soluble as Form III at any temperature in the studied range.
|
Key finding from melting point analysis: Melting point differences between polymorphs have a very modest effect on solubility ratio. Even extreme melting point differences (37.5°C) produce less than a 2:1 solubility ratio — confirming the fundamental principle that polymorphs of the same compound rarely differ dramatically in solubility. |
|---|
The theoretical treatment of carbamazepine polymorphs reveals a principle that holds broadly across pharmaceutical compounds: the intrinsic thermodynamic solubility difference between polymorphs is typically modest — rarely exceeding a few-fold ratio under physiologically relevant conditions. This has direct, practical consequences for drug development strategy:
When the drug is already highly water-soluble, minor differences in polymorph solubility have negligible impact on oral absorption. The formulation specification for these compounds typically focuses on polymorphic physical and mechanical properties — crystal habit, compressibility, flow, bulk density — rather than solubility. DSC characterization still confirms polymorph identity and purity, but solubility modeling is not the primary use case.
For drugs with intrinsically low aqueous solubility, even a modest 1.5× or 2× solubility advantage from a metastable polymorph can be clinically meaningful. Dissolution rate — the rate at which the drug enters solution — depends on both solubility and surface area, and a higher-solubility polymorph may achieve faster dissolution rates that translate into measurably higher Cmax and AUC. For these compounds, the DSC-derived solubility ratio calculation is a direct input to formulation risk assessment: if the metastable polymorph’s solubility advantage is modest, the risk of using it in a dosage form may outweigh the bioavailability benefit.
Even when solubility differences between polymorphs are modest, non-solubility properties may necessitate strict polymorphic control during formulation development and manufacturing:
In all of these scenarios, DSC is the primary analytical technique for confirming polymorph identity, detecting polymorphic conversion during processing or storage, and measuring the calorimetric properties — melting point, heat of fusion, transition enthalpy — that feed directly into formulation decision-making.
The solubility modeling application demonstrated with carbamazepine is one of several critical differential scanning calorimetry applications in pharmaceutical drug development. The table below summarises key DSC applications across the preformulation-to-QC lifecycle:
|
Development Stage |
DSC Application |
Key Measurement |
Decision Supported |
|---|---|---|---|
|
Preformulation |
Polymorph screening and identification |
Melting point (Tm) and heat of fusion (ΔHf) for each crystal form |
Which polymorphic form(s) exist; which is thermodynamically stable |
|
Preformulation |
Solubility ratio modeling (this article) |
ΔHf and Tm from DSC → solubility ratio calculation via Eq. (1) |
Whether the metastable form offers a meaningful bioavailability advantage |
|
Preformulation |
Polymorphic transition temperature determination |
Calculate T at which solubility curves of two polymorphs intersect |
Storage temperature limits; whether a thermodynamic inversion is relevant at use temperature |
|
Preformulation |
Drug-excipient compatibility screening |
Disappearance or shift of drug melting endotherm in physical mixtures |
Which excipients are physically compatible without solid-state interaction |
|
Formulation development |
Amorphous content quantification |
ΔHf of crystalline drug in formulation vs. pure crystalline reference |
Degree of crystallinity; extent of amorphization during processing |
|
Scale-up & manufacturing |
Polymorphic purity control |
Melting point and enthalpy of API batch vs. specification |
Whether batch meets polymorphic form specification before formulation |
|
QC / Stability testing |
Polymorphic conversion detection |
Changes in melting endotherm position or shape on stability samples |
Whether product has undergone solid-state conversion during storage |
Accurate detection of melting point and heat of fusion is the foundation of all the differential scanning calorimetry applications described above. The DSC 600 (Figure 4; alt text: AMI DSC 600 differential scanning calorimeter with high-precision heat flow sensor, -150°C to 600°C temperature range, ±0.1°C accuracy, ±0.01°C precision) is designed for exactly this level of precision in pharmaceutical and materials characterization.
|
Related reading: For a full worked example of DSC and TGA applied simultaneously to pharmaceutical compound characterization — including polymorph differentiation, heating rate effects, and moisture analysis — see our article on thermal analysis in the pharmaceutical field. For DSC applied to organic cosmetic formulations including wax and lipid melting behavior, see DSC analysis of lipstick thermal properties. |
|---|
Differential scanning calorimetry provides the two calorimetric parameters — heat of fusion and melting temperature — that are the direct inputs to the thermodynamic solubility equation for pharmaceutical polymorph analysis. Applied to carbamazepine Forms I and III, this differential scanning calorimetry application demonstrates that even extreme theoretical variations in ΔHf (up to 9.0 kJ/mol) or melting point difference (up to 37.5°C) produce modest solubility ratios — generally below 3:1 at room temperature — confirming the fundamental principle that polymorphs rarely differ dramatically in solubility.
This thermodynamic insight has direct practical value for preformulation strategy: for highly soluble drugs, polymorphic solubility differences are unlikely to impact performance; for poorly soluble drugs, even the modest differences that thermodynamics allows may be clinically relevant and worthy of polymorphic form selection. In both cases, DSC-measured melting point and heat of fusion provide the quantitative foundation for making those decisions before resource-intensive dissolution studies are undertaken.
Explore AMI’s full range of thermal analysis instruments, including the DSC 600 for pharmaceutical polymorph characterization. Visit the AMI Technical Library for further application notes on DSC, TGA, and thermal analysis across pharmaceutical, polymer, and advanced materials applications.
One of the most powerful differential scanning calorimetry applications in pharmaceutical development is polymorph characterization and solubility modeling. DSC directly measures the melting temperature (Tm) and heat of fusion (ΔHf) of each crystal form of a drug compound. These two values feed into a thermodynamic solubility equation that predicts the relative solubility of different polymorphic forms across a range of temperatures — without requiring solubility measurements. This application supports polymorph selection strategy, formulation risk assessment, and bioavailability prediction during preformulation.
Pharmaceutical polymorphism is the ability of a drug compound to crystallize in more than one distinct crystal lattice arrangement. Each polymorphic form has the same molecular formula but different packing — producing different melting points, heats of fusion, solubilities, densities, and sometimes different chemical stability. Polymorphism matters because the crystal form of an API in a solid dosage form directly determines dissolution rate and potentially bioavailability, particularly for poorly soluble BCS Class II and IV drugs. Regulatory agencies require polymorph identification and control throughout drug development and manufacturing.
In a DSC experiment, the drug sample is heated at a controlled rate. When a crystalline solid melts, it absorbs heat from its surroundings — producing an endothermic peak in the DSC heat flow signal. The temperature at the peak of this endotherm is the melting point (Tm). The area under the peak — integrated against a carefully drawn baseline — gives the enthalpy of fusion (ΔHf) in J/g or kJ/mol. Both values are directly measurable from a single DSC run on a few milligrams of crystalline sample. For the solubility ratio calculation in this article, both measurements need to be accurate to within approximately ±0.5°C (Tm) and ±1 kJ/mol (ΔHf) to produce reliable solubility ratio predictions.
No — and this is the key practical finding from thermodynamic solubility modeling using DSC data. As demonstrated with carbamazepine, even large theoretical differences in heat of fusion (up to 9.0 kJ/mol) or melting point (up to 37.5°C) produce solubility ratios typically below 3:1 at room temperature. This thermodynamic constraint means that polymorphic solubility advantages are intrinsically modest. For highly soluble drugs, these differences rarely impact product performance. For poorly soluble drugs, a 1.5× to 2× solubility advantage can be clinically meaningful, but the metastable form carrying that advantage may also be physically unstable — creating formulation and regulatory complexity.
Even when solubility differences between polymorphs are modest, other physical properties often require strict polymorphic control: crystal density and true density (affecting compaction and tablet hardness), crystal habit and shape (affecting powder flow, blending, and content uniformity), compressibility (affecting tableting behavior), hygroscopicity and hydrate formation tendency (affecting storage stability and packaging specification), and chemical degradation kinetics (affecting shelf life and regulatory ICH stability requirements). DSC detects polymorphic identity, conversion, and purity across all of these use cases as the primary screening tool.
Understand reactor design equations for batch, CSTR, and plug flow reactors. A practical guide for catalytic scientists using AMI lab reactor instruments.
Learn how temperature swing adsorption (TSA) removes moisture from natural gas, shale gas, and compressed air. Explore AMI instruments for TSA adsorbent research.
Compare lab scale catalytic reactors for screening, kinetic studies, and scale-up. Fixed-bed, CSTR, batch, and recirculating reactor selection guide from AMI.